Skip to content

Stay tuned for the finalists of the Shauna M. Sorrells Program

G2G Bio Bulletin – October 31, 2026

Updates from Washington

Congress: Both chambers are out of session until after the election, and activity is limited.
  • House Appropriations Committee Ranking Member Rosa DeLauro (D-CT) has introduced the Medicare for America Act, which would open an expanded Medicare program to cover all interested U.S. residents, while continuing to preserve private and employer sponsored insurance.
  • House Energy & Commerce Committee Ranking Member, Frank Pallone (D-NJ) has asked the Government Accountability Office (GAO) to review the Trump Administration's claims about savings from the TrumpRx drug discount platform.
  • Outgoing Senate Health, Education, Labor, and Pensions (HELP) Committee Chair Bill Cassidy has released a draft bill, The PATIENT AI Act, that establishes a regulatory framework and payment pathways for healthcare AI tools. Feedback on the proposal is being accepted until December 1.
  • Senate Democrats, led by Finance Committee Ranking Member Ron Wyden (D-OR) and HELP Committee Ranking Member Bernie Sanders (I-VT), have written to health insurance companies offering plans through ACA exchanges, asking that they provide information on their involvement in the Trump Administration’s anti-fraud efforts. The lawmakers allege that these activities have resulted in a significant number of improper coverage terminations.
Administration & Agencies:
  • ARPA-H: Agency Director Alicia Jackson is on administrative leave amid an internal HHS ethics review of potential conflicts of interest involving her financial stakes in companies that may receive ARPA-H funding or benefit from recent HHS policy decisions.
  • FDA
    • The agency has issued a draft guidance on how genome editing (GE) products that include multiple variants can be submitted in a single Biologics License Application. If implemented, the proposal would significantly lower the high regulatory burdens that stymie the approval of personalized GE products for ultra rare diseases. Comments on the proposal are due November 27.
    • The agency has issued final guidance for how drug companies can develop, distribute, and label mobile apps designed to be used alongside their prescription medicines. The regulation addresses questions on labeling, prescribing information and data to be submitted to the FDA.
  • CMS
    • A federal judge has ruled against the Administration’s effort to narrow medical frailty exemptions to Medicaid work requirements mandated by OBBBA. The new rules are set to roll out on January 1, but this ruling would provide states an additional six months to set their criteria for medical frailty.
  • White House, Other HHS Agencies & Departments:
    • Healthcare Data: HHS has released a final rule that significantly reduces rules governing electronic healthcare record privacy and security. The agency has stated that the goal of the deregulation is to expand competition in the health IT space, although stakeholders have warned about potential harms to patients.
    • Imports from China: The Department of Homeland Security has announced a ban on imports of products made by the Chinese companies BGI Genomics, BGI Group, and MGI, alleging those firms' involvement in practices that violate the Uyghur Forced Labor Prevention Act.
    • Peptides: HHS has issued a policy that temporarily permits compounding pharmacies to produce a limited number of peptide products.
    • Pharmacy Benefit Managers (PBMs): The Labor Department has issued a final rule that would require PBMs to disclose payments they receive from drug manufacturers and pharmacies, as well as spread compensations and price protection arrangements.
    • Congressionally Directed Medical Research Programs: The Traumatic Brain Injury and Psychological Health Research Program (TBIPHRP) has issued a request for information to solicit input that will help shape future research priorities. Responses are due December 4.